Investigation of the protective role of fisetin against doxorubicin-induced liver injury in rats

Year 2025, EARLY ONLINE, 1 - 10

Ömür Gülsüm Deniz

https://doi.org/10.18621/eurj.1751730

Abstract

Objectives: The aim of the present research was to histopathologically investigate the potentially advantageous effects of the flavonoid fisetin on liver damage induced by the chemotherapeutic drug doxorubicin (DOX) in rats.

Methods: Thirty-five Wistar albino female rats were randomized in five as Control, dimethyl sulfoxide (DMSO, solvent), fisetin (50 mg/kg/day; 7 days i.p.), DOX (single dose, 10 mg/kg; i.p.) and DOX+fisetin (10 mg/kg DOX+50 mg/kg/day fisetin for 7 days). Livers were harvested, fixed in 10% formalin, and processed for histopathology by hematoxylin-eosin staining. Central to these analyses of damage parameters for inflammation, sinusoidal dilatation, and hepatocyte injury were examined histopathologically.

Results: The DOX group had severe hepatocyte degeneration, inflammation, and sinusoidal dilatation. In contrast, the DOX+fisetin group expressed mild sinusoidal dilatation and insignificant inflammatory change. In this context, statistical significance was found between the DOX group and the DOX+fisetin group in terms of hepatocyte degeneration and inflammation (P<0.01), and sinusoidal dilatation (P=0.038). However, no significant differences were observed in between the Control, fisetin, and DMSO groups (P=1.000).

Conclusions: Fisetin conferred substantial histological protection from DOX-induced liver injury in rats. The amelioration may have resulted from the fisetin's antioxidant, anti-inflammatory, and perhaps membrane-stabilizing effects, thus proving its potential as a hepatoprotective agent.

Keywords

Doxorubicin , fisetin , histopathology , liver , rat

Ethical Statement

This study was approved by the Bolu Abant İzzet Baysal University animal experiments local ethics committee under decision no 2025/24 and date 16/04/2025. All experimental procedures were conducted in compliance with the U.K. Animals (Scientific Procedures) Act, 1986, the EU Directive 2010/63/EU for animal experimentation, and the National Institutes of Health guidelines for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978).

References

• 1. Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the gad and the ugly effect. Curr Med Chem. 2009;16(25):3267-3285. doi: 10.2174/092986709788803312.
• 2. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440-446. doi: 10.1097/FPC.0b013e32833ffb56.
• 3. Li S, Yuan S, Zhao Q, Wang B, Wang X, Li K. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed Pharmacother. 2018;100:441-447. doi: 10.1016/j.biopha.2018.02.055.
• 4. Licata S, Saponiero A, Mordente A, Minotti G. Doxorubicin metabolism and toxicity in human myocardium: Role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol. 2000;13(5):414-420. doi: 10.1021/tx000013q.
• 5. Edwardson D, Narendrula R, Chewchuk S, Mispel-Beyer K, Mapletoft J, Parissenti A. Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines. Curr Drug Metab. 2015;16(6):412-426. doi: 10.2174/1389200216888150915112039.
• 6. Asensio-López MC, Soler F, Pascual-Figal D, Fernández-Belda F, Lax A. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS One. 2017;12(2):e0172803. doi: 10.1371/journal.pone.0172803.
• 7. Jakobs P, Serbulea V, Leitinger N, Eckers A, Haendeler J. Nuclear factor (Erythroid-Derived 2)-like 2 and thioredoxin-1 in atherosclerosis and ischemia/reperfusion injury in the heart. Antioxid Redox Signal. 2017;26(12):630-644. doi: 10.1089/ars.2016.6795.
• 8. Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: A common factor in the complex milieu of anthracycline cardiotoxicity. Oxid Med Cell Longev. 2017;2017:1521020. doi: 10.1155/2017/1521020.
• 9. Elsherbiny NM, El-Sherbiny M. Thymoquinone attenuates doxorubicin-induced nephrotoxicity in rats: Role of Nrf2 and NOX4. Chem Biol Interact. 2014;223:102-108. doi: 10.1016/j.cbi.2014.09.015.
• 10. Barakat BM, Ahmed HI, Bahr HI, Elbahaie AM. Protective effect of boswellic acids against doxorubicin-induced hepatotoxicity: Impact on Nrf2/HO-1 defense pathway. Oxid Med Cell Longev. 2018;2018:8296451. doi: 10.1155/2018/8296451.
• 11. Alasmari AF, Alharbi M, Alqahtani F, et al. Diosmin alleviates doxorubicin-induced liver injury via modulation of oxidative stress-mediated hepatic inflammation and apoptosis via NfkB and MAPK pathway: A preclinical study. Antioxidants (Basel). 2021;10(12):1998. doi: 10.3390/antiox10121998.
• 12. Grant DM. Detoxification pathways in the liver. J Inherit Metab Dis. 1991;14(4):421-430. doi: 10.1007/BF01797915.
• 13. Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139(7):876-887. doi: 10.5858/arpa.2014-0214-RA.
• 14. Shivakumar P, Usha Rani M, Gopala Reddy A, Anjaneyulu Y. A study on the toxic effects of doxorubicin on the histology of certain organs. Toxicol Int. 2012;19(3):241-244. doi: 10.4103/0971-6580.103656.
• 15. Mansouri E, Jangaran A, Ashtari A. Protective effect of pravastatin on doxorubicin-induced hepatotoxicity. Bratisl Lek Listy. 2017;118(5):273-277. doi: 10.4149/BLL_2017_054.
• 16. Martinel Lamas DJ, Nicoud MB, Sterle HA, et al. Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell Death Discov. 2015;1:15059. doi: 10.1038/cddiscovery.2015.59.
• 17. Mete R, Oran M, Topcu B, et al. Protective effects of onion (Allium cepa) extract against doxorubicin-induced hepatotoxicity in rats. Toxicol Ind Health. 2016;32(3):551-557. doi: 10.1177/0748233713504807.
• 18. Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats: The effects of vitamin E and catechin. Toxicology. 2005;209(1):39-45. doi: 10.1016/j.tox.2004.12.003.
• 19. Yao PA, Wu R, Zhang YL, et al. Alleviation of doxorubicin-induced hepatic toxicity with fermented Cordyceps sinensis via regulating hepatic energy metabolism in rats. Pharmacogn Mag. 2018;14(56):283-289. doi: 10.4103/pm.pm_354_17.
• 20. Li D, Liu X, Pi W, et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signaling pathway activation. Front Pharmacol. 2022;12:808480. doi: 10.3389/fphar.2021.808480.
• 21. Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: A dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19(2):151-162. doi: 10.1089/ars.2012.4901.
• 22. Afzal M, Alarifi A, Karami AM, et al. Antiproliferative mechanisms of a polyphenolic combination of kaempferol and fisetin in triple-negative breast cancer cells. Int J Mol Sci. 2023;24(7):6393. doi: 10.3390/ijms24076393.
• 23. Sundarraj K, Raghunath A, Panneerselvam L, Perumal E. Fisetin, a phytopolyphenol, targets apoptotic and necroptotic cell death in HepG2 cells. Biofactors. 2020;46(1):118-135. doi: 10.1002/biof.1577.
• 24. Ma T, Kandhare AD, Mukherjee-Kandhare AA, Bodhankar SL. Fisetin, a plant flavonoid ameliorates doxorubicin-induced cardiotoxicity in experimental rats: the decisive role of caspase-3, COX-II, cTn-I, iNOs and TNF-α. Mol Biol Rep. 2019;46(1):105-118. doi: 10.1007/s11033-018-4450-y.
• 25. Lin KH, Ramesh S, Agarwal S, et al. Fisetin attenuates doxorubicin-induced cardiotoxicity by inhibiting the insulin-like growth factor II receptor apoptotic pathway through estrogen receptor-α/-β activation. Phytother Res. 2023;37(9):3964-3981. doi: 10.1002/ptr.7855.
• 26. Prasath GS, Subramanian SP. Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2011;668(3):492-496. doi: 10.1016/j.ejphar.2011.07.021.
• 27. Naeimi AF, Alizadeh M. Antioxidant properties of the flavonoid fisetin: An updated review of in vivo and in vitro studies. Trends Food Sci Technol. 2017;70:34-44. doi: 10.1016/j.tifs.2017.10.003.
• 28. Althunibat OY, Al Hroob AM, Abukhalil MH, et al. Fisetin ameliorates oxidative stress, inflammation and apoptosis in diabetic cardiomyopathy. Life Sci. 2019;221:83-92. doi: 10.1016/j.lfs.2019.02.017.
• 29. Li D, Liu X, Pi W, et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signaling pathway activation. Front Pharmacol. 2022;12:808480. doi:10.3389/fphar.2021.808480.
• 30. El Shaer DF, Abd El Halim HI. The possible ameliorating role of fisetin on hepatic changes induced by fluoxetine in adult male albino rats: histological, immunohistochemical, and biochemical study. J Microsc Ultrastruct. 2023;11(3):161-171. doi: 10.4103/jmau.jmau_84_22.
• 31. Kayali A, Bora ES, Acar H, Yilmaz G, Erbaş O. Fisetin ameliorates methotrexate induced liver fibrosis. Eur Rev Med Pharmacol Sci. 2024;28(8):3112-3119. doi: 10.26355/eurrev_202404_36027.
• 32. Hawi AJ, Al-Shawi NN. Evaluation of the effect of fisetin against cyclophosphamide-induced myelosuppression and oxidative stress in male albino rats. Iraqi J Pharm Sci. 2023;32(2):120-127. doi: 10.31351/vol32iss2pp120-127.
• 33. Cecen E, Dost T, Culhaci N, Karul A, Ergur B, Birincioglu M. Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pac J Cancer Prev. 2011;12(10):2697-2704.
• 34. Elma B, Mammadov R, Süleyman H, et al. The effect of rutin on experimentally induced acute heart contusion in rats: Biochemical and histopathological evaluation. Ulus Travma Acil Cerrahi Derg. 2022;28(8):1073-1081. doi: 10.14744/tjtes.2021.97760.
• 35. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952-964. doi: 10.1016/j.jhep.2011.08.025.
• 36. Ballet F, Vrignaud P, Robert J, Rey C, Poupon R. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver. Cancer Chemother Pharmacol. 1987;19(3):240-245. doi: 10.1007/BF00252979.
• 37. Bachur NR, Fox BM. Loss of fluorescence by anthracycline antibiotics: effects of xanthine oxidase and identification of the nonfluorescent metabolites. Cancer Res. 1987;47(4):1036-1039.
• 38. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: Effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet. 2005;44(2):187-200. doi: 10.2165/00003088-200544020-00004.
• 39. Song S, Chu L, Liang H, et al. Protective effects of dioscin against doxorubicin-induced hepatotoxicity via regulation of SIRT1/FoxO1/NF-κB signal. Front Pharmacol. 2019;10:1030. doi: 10.3389/fphar.2019.01030.
• 40. El-Sayyad HI, Ismail MF, Shalaby FM, et al. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int J Biol Sci. 2009;5(5):466-473. doi: 10.7150/ijbs.5.466.
• 41. Chaudhary D, Khatiwada S, Sah SK, Tamang MK, Bhattacharya S, Jha CB. Effect of doxorubicin on histomorphology of liver of wistar albino rats. J Pharm Pharmacol. 2016;4(4):186–190. doi: 10.17265/2328-2150/2016.04.005.
• 42. Orak N, Çakmak Arslan G, Kaya ST. An Evaluation of damages caused by doxorubicin in liver tissue and potential protective effect of propolis on these damages. Konuralp Med J. 2022;14(1):104-113. doi: 10.18521/ktd.1049919.
• 43. Maslova GS, Skrypnyk IM, Yeroshenko GA. Morphological features of doxorubicin-induced liver damage associated with nonalcoholic steatohepatitis. World Med Biol. 2020;16(73):189-194. doi: 10.26724/2079-8334-2020-3-73-189-194.
• 44. Constantin RP, Constantin J, Pagadigorria CLS, et al. Prooxidant activity of fisetin: Effects on energy metabolism in the rat liver. J Biochem Mol Toxicol. 2011;25(2):117-126. doi: 10.1002/jbt.20367.
• 45. Sun Q, Zhang W, Zhong W, Sun X, Zhou Z. Dietary fisetin supplementation protects against alcohol-induced liver injury in mice. Alcohol Clin Exp Res. 2016;40(10):2076-2084. doi: 10.1111/acer.13172.
• 46. Jeon T-Il, Park JW, Ahn J, Jung CH, Ha TY. Fisetin protects against hepatosteatosis in mice by inhibiting miR-378. Mol Nutr Food Res. 2013;57(11):1931-1937. doi: 10.1002/mnfr.201300071.
• 47. Rauf A, Abu-Izneid T, Imran M, et al. Therapeutic potential and molecular mechanisms of the multitargeted flavonoid fisetin. Curr Top Med Chem. 2023;23(21):2075-2096. doi: 10.2174/1568026623666230710162217.
• 48. Singh M, Kadhim MM, Jalil AT, et al. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity. Cancer Cell Int. 2023;23(1):88. doi: 10.1186/s12935-023-02936-4.
• 49. El-Fadaly AA, Afifi NA, El-Eraky W, et al. Fisetin alleviates thioacetamide-induced hepatic fibrosis in rats by inhibiting Wnt/β-catenin signaling pathway. Immunopharmacol Immunotoxicol. 2022;44(3):355-366. doi: 10.1080/08923973.2022.2047198.
• 50. Khairani D, Ilyas S. Flavonoids for hepatoprotection: Potential natural approaches to mitigate doxorubicin-induced liver toxicity: A mini review. J Med Pharm Chem Res. 2025;7(7):1464-1485. doi: 10.48309/JMPCR.2025.471206.1367.
• 51. Li Z, Wang Y, Zhang Y, et al. Protective effects of fisetin on hepatic ischemia-reperfusion injury through alleviation of apoptosis and oxidative stress. Arch Med Res. 2021;52(2):163-173. doi: 10.1016/j.arcmed.2020.10.009.
• 52. Zhang J, Zhao L, Hu C, et al. Fisetin prevents acetaminophen-induced liver injury by promoting autophagy. Front Pharmacol. 2020;11:162. doi: 10.3389/fphar.2020.00162.
• 53. Nayak S, Rakshit D, Yadav V, et al. Protective effect of fisetin on subacute and chronic arsenic and fluoride co-exposure induced hepatic, renal and cardiac toxicities in mice. J Biochem Mol Toxicol. 2025;39(2):e70113. doi: 10.1002/jbt.70113.